Nuclidium Raises €84M Series B to Advance Copper-Based Cancer Radiopharmaceuticals

Nuclidium AG, a Swiss-German clinical-stage biotechnology company, has raised approximately $99 million in a Series B funding round co-led by Angelini Ventures, Kurma Growth Opportunities Fund, Wellington Partners, and Neva SGR. The investment will accelerate the clinical development of Nuclidium's innovative copper-based theranostic platform using Copper-61 for diagnostics and Copper-67 for therapeutics across multiple oncology indications, including metastatic prostate and breast cancers. Early clinical data suggest superior lesion detection, higher tumor-to-background ratios, and a favorable safety profile compared to existing standards, highlighting the platform's potential to overcome current limitations in radiotheranostics. Nuclidium emphasizes the advantages of copper isotopes, such as higher therapeutic doses, lower radiation burden, easier manufacturing, and reduced radioactive waste without the need for a nuclear reactor. The company plans to expand its global production and manufacturing network while strengthening collaborations with hospitals and academic centers internationally. Key appointments to its board include Regina Hodits of Angelini Ventures and new independent directors Tony Rosenberg and David Meek, supporting Nuclidium's growth and strategic development.